We’re reimagining diagnostics by

READING THE IMMUNE SYSTEM

Inflammatix Receives Breakthrough Device Designation from FDA for TriVerity™

Regulatory Milestone Designed to Expedite Path to FDA Clearance and CMS Coverage
click to read more

Host Response Diagnostics

Delivering precision medicine on demand

Inflammatix device with cartridge

Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Product in development, is not for sale, and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Our tests are addressing significant clinical needs in acute infection and sepsis diagnosis that affect millions of people

Products in development, not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

Significant clinical needs in acute infection and sepsis diagnosis

Based on US CDC numbers. Numbers also referenced from Martin, NEJM 2003; Donnelly, Antimicrob. Ag Chemo 2013; Hasegawa, PIDJ 2015; Goto, J Am Ger Soc 2016; Magill, NEJM 2014; Horeczko, West JEM 2014; Fleming-Dutra, JAMA 2016.

In the News

Recent notable news stories

360 Dx Logo

Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up

January 02, 2024

bioworld

Inflammatix sepsis test scores FDA breakthrough device designation

November 28, 2023

360 Dx Logo

Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test

November 28, 2023

The Wall Street Journal

Your medical devices are getting smarter. Can the FDA keep them safe?

October 9, 2023

Also covered by

Stay in touch with social updates:
Find out the latest news.